Literature DB >> 22397609

Functional cardiac tissue engineering.

Brian Liau1, Donghui Zhang, Nenad Bursac.   

Abstract

Heart attack remains the leading cause of death in both men and women worldwide. Stem cell-based therapies, including the use of engineered cardiac tissues, have the potential to treat the massive cell loss and pathological remodeling resulting from heart attack. Specifically, embryonic and induced pluripotent stem cells are a promising source for generation of therapeutically relevant numbers of functional cardiomyocytes and engineering of cardiac tissues in vitro. This review will describe methodologies for successful differentiation of pluripotent stem cells towards the cardiovascular cell lineages as they pertain to the field of cardiac tissue engineering. The emphasis will be placed on comparing the functional maturation in engineered cardiac tissues and developing heart and on methods to quantify cardiac electrical and mechanical function at different spatial scales.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22397609      PMCID: PMC3616389          DOI: 10.2217/rme.11.122

Source DB:  PubMed          Journal:  Regen Med        ISSN: 1746-0751            Impact factor:   3.806


  188 in total

1.  Chronic stretch of engineered heart tissue induces hypertrophy and functional improvement.

Authors:  C Fink; S Ergün; D Kralisch; U Remmers; J Weil; T Eschenhagen
Journal:  FASEB J       Date:  2000-04       Impact factor: 5.191

2.  Single-channel currents recorded from membrane of denervated frog muscle fibres.

Authors:  E Neher; B Sakmann
Journal:  Nature       Date:  1976-04-29       Impact factor: 49.962

3.  Selection of ventricular-like cardiomyocytes from ES cells in vitro.

Authors:  M Müller; B K Fleischmann; S Selbert; G J Ji; E Endl; G Middeler; O J Müller; P Schlenke; S Frese; A M Wobus; J Hescheler; H A Katus; W M Franz
Journal:  FASEB J       Date:  2000-12       Impact factor: 5.191

4.  Effects of electrical fields on cardiomyocyte differentiation of embryonic stem cells.

Authors:  H Sauer; G Rahimi; J Hescheler; M Wartenberg
Journal:  J Cell Biochem       Date:  1999-12-15       Impact factor: 4.429

5.  Downregulation of connexin 45 gene products during mouse heart development.

Authors:  S Alcoléa; M Théveniau-Ruissy; T Jarry-Guichard; I Marics; E Tzouanacou; J P Chauvin; J P Briand; A F Moorman; W H Lamers; D B Gros
Journal:  Circ Res       Date:  1999-06-25       Impact factor: 17.367

6.  STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells.

Authors:  T Matsuda; T Nakamura; K Nakao; T Arai; M Katsuki; T Heike; T Yokota
Journal:  EMBO J       Date:  1999-08-02       Impact factor: 11.598

7.  Synthetic strands of neonatal mouse cardiac myocytes: structural and electrophysiological properties.

Authors:  S P Thomas; L Bircher-Lehmann; S A Thomas; J Zhuang; J E Saffitz; A G Kléber
Journal:  Circ Res       Date:  2000-09-15       Impact factor: 17.367

8.  Observations on the ultrastructure of developing myocardium of rat embryos.

Authors:  K J Chacko
Journal:  J Morphol       Date:  1976-11       Impact factor: 1.804

9.  Myoblast transplantation for heart failure.

Authors:  P Menasché; A A Hagège; M Scorsin; B Pouzet; M Desnos; D Duboc; K Schwartz; J T Vilquin; J P Marolleau
Journal:  Lancet       Date:  2001-01-27       Impact factor: 79.321

Review 10.  A genetic blueprint for cardiac development.

Authors:  D Srivastava; E N Olson
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

View more
  37 in total

Review 1.  Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies.

Authors:  Evangeline Tzatzalos; Oscar J Abilez; Praveen Shukla; Joseph C Wu
Journal:  Adv Drug Deliv Rev       Date:  2015-09-30       Impact factor: 15.470

Review 2.  Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues.

Authors:  Nicole T Feric; Milica Radisic
Journal:  Adv Drug Deliv Rev       Date:  2015-05-05       Impact factor: 15.470

3.  Engineering a naturally-derived adhesive and conductive cardiopatch.

Authors:  Brian W Walker; Roberto Portillo Lara; Chu Hsiang Yu; Ehsan Shirzaei Sani; William Kimball; Shannon Joyce; Nasim Annabi
Journal:  Biomaterials       Date:  2019-03-21       Impact factor: 12.479

4.  Cell number per spheroid and electrical conductivity of nanowires influence the function of silicon nanowired human cardiac spheroids.

Authors:  Yu Tan; Dylan Richards; Robert C Coyle; Jenny Yao; Ruoyu Xu; Wenyu Gou; Hongjun Wang; Donald R Menick; Bozhi Tian; Ying Mei
Journal:  Acta Biomater       Date:  2017-01-10       Impact factor: 8.947

5.  Cell-laden microengineered and mechanically tunable hybrid hydrogels of gelatin and graphene oxide.

Authors:  Su Ryon Shin; Behnaz Aghaei-Ghareh-Bolagh; Tram T Dang; Seda Nur Topkaya; Xiguang Gao; Seung Yun Yang; Sung Mi Jung; Jong Hyun Oh; Mehmet R Dokmeci; Xiaowu Shirley Tang; Ali Khademhosseini
Journal:  Adv Mater       Date:  2013-09-01       Impact factor: 30.849

Review 6.  Cardiovascular Bio-Engineering: Current State of the Art.

Authors:  Teresa Simon-Yarza; Isabelle Bataille; Didier Letourneur
Journal:  J Cardiovasc Transl Res       Date:  2017-03-06       Impact factor: 4.132

Review 7.  Physiologic, Pathologic, and Therapeutic Paracrine Modulation of Cardiac Excitation-Contraction Coupling.

Authors:  Joshua Mayourian; Delaine K Ceholski; David M Gonzalez; Timothy J Cashman; Susmita Sahoo; Roger J Hajjar; Kevin D Costa
Journal:  Circ Res       Date:  2018-01-05       Impact factor: 17.367

Review 8.  Biomaterials in myocardial tissue engineering.

Authors:  Lewis A Reis; Loraine L Y Chiu; Nicole Feric; Lara Fu; Milica Radisic
Journal:  J Tissue Eng Regen Med       Date:  2014-07-28       Impact factor: 3.963

9.  Three-dimensional elastomeric scaffolds designed with cardiac-mimetic structural and mechanical features.

Authors:  Rebekah A Neal; Aurélie Jean; Hyoungshin Park; Patrick B Wu; James Hsiao; George C Engelmayr; Robert Langer; Lisa E Freed
Journal:  Tissue Eng Part A       Date:  2012-11-28       Impact factor: 3.845

10.  Pluripotent stem cells as a platform for cardiac arrhythmia drug screening.

Authors:  Jordan S Leyton-Mange; David J Milan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.